Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Under Armour Inc Class A (UA) Price & Performance

CVS Health CorpTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Under Armour Inc Class A — how do they compare? CVS Health Corp trades at $86.4 (market cap $112.29B), while Under Armour Inc Class A trades at $4.74 (market cap $2.07B). The key difference: CVS Health Corp is far larger — about 54.2× Under Armour Inc Class A's market cap, and CVS Health Corp pays a 3.03% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Under Armour Inc Class A for 18 Days on average.

CVSUA
Market Cap
$112.29B$2.07B
Volume
7,763,6762,680,141
Sector
HealthConsumer Cyclical
52-Week High
$110.60$7.88
52-Week Low
$70.08$3.96
Typical Hold Time
83 Days18 Days
Enterprise Value
$174.64B$3.05B
Dividend Yield
3.03%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.

The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.

Under Armour Inc Class A

Under Armour (UA) trades at $4.70, down 0.42% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company faces significant fundamental challenges with declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability metrics, including a -9.99% net income margin and -29.82% ROE. Recent earnings show volatility with two beats and one miss in the last four quarters, while cash flow remains negative across all categories.

The outlook remains challenging with declining revenue trends and persistent profitability issues offset by relatively low valuation multiples. Investment opportunity exists if management can stabilize sales and improve margins, but risks include continued consumer demand weakness and competitive pressures in the athletic apparel sector. Analyst sentiment is mixed with 41% buy ratings but growing concerns about the company's turnaround prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA →